Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API
Radnostix reported Q3 2026 revenue of $2.57 million, down 22% year-over-year, with the nine-month top line down 25% to $7.62 million and net loss widening to $0.84 million for the quarter. The declines were driven by delayed Cobalt contracts awaiting NRC sealed-source amendments, a global cobalt-57 supply interruption, and two voluntary Theranostics recalls — though Theranostics sales grew 15% YoY and Gd-153 shipments resumed after a multi-year outage.
Key figures
- Revenue
- 2571035
- Guidance
- Delayed ~$1.2 million of contracted Cobalt sales moved from 2H 2026 to Q1 2027; EasyFill and RadVent commercialization targeted Q1 2027
- Revenue Yoy
- -22%
- Deal Value Usd
- 13500000
- Credit facility
- $1.0 million revolving line of credit with Bank of Commerce, 12-month term, prime rate, secured
- Q3 gross margin
- 59%
- Restricted cash
- 1530000
- Nine month revenue
- 7621744
- Theranostics q3 yoy
- 15%
- Cobalt q3 revenue yoy
- -88%
- Nine month revenue yoy
- -25%
- Nine month gross margin
- 53%
- Theranostics q3 revenue
- 1710000
- Recall lost revenue estimate
- 850000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.